Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
MEDICINE: PPARs as Therapeutic Targets: Reverse Cardiology?
Jorge Plutzky
Formation of the atherosclerotic lesions that lead to myocardial infarction is determined in part by inflammatory responses such as the production of lipid-laden macrophages. In his Perspective, Plutzky highlights the parts played by PPAR nuclear receptors, especially PPAR- (Lee et al.), in the modulation of inflammatory responses and hence atherosclerosis.
The author is in the Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. E-mail: jplutzky{at}rics.bwh.harvard.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
REPORTS
Chih-Hao Lee, Ajay Chawla, Ned Urbiztondo, Debbie Liao, William A. Boisvert, and Ronald M. Evans (17 October 2003) Science302 (5644), 453.
[DOI: 10.1126/science.1087344] |Abstract »|Full Text »|PDF »|Supporting Online Material »
Y. Takata, J. Liu, F. Yin, A. R. Collins, C. J. Lyon, C.-H. Lee, A. R. Atkins, M. Downes, G. D. Barish, R. M. Evans, et al. (2008)
PNAS
105, 4277-4282
|Abstract »|Full Text »|PDF »
The Peroxisome Proliferator Activated Receptor-{gamma} Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance.
C. Werner, C. H. Kamani, C. Gensch, M. Bohm, and U. Laufs (2007)
Diabetes
56, 2609-2615
|Abstract »|Full Text »|PDF »
Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPAR{alpha}.
J. Plutzky (2007)
Diabetes and Vascular Disease Research
4, S12-S14
|Abstract »|PDF »
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets.
Immunomodulation Strategies for Preventing Vascular Disease of the Brain and Heart: Workshop Summary.
J. Hallenbeck, G. del Zoppo, T. Jacobs, A. Hakim, S. Goldman, U. Utz, A. Hasan, and for the Immunomodulation Workshop Participants (2006)
Stroke
37, 3035-3042
|Abstract »|Full Text »|PDF »
Regulation of Vascular Inflammation and Remodeling by ETS Factors.
X. Fang, S. Hu, B. Xu, G. D. Snyder, S. Harmon, J. Yao, Y. Liu, B. Sangras, J. R. Falck, N. L. Weintraub, et al. (2006)
Am J Physiol Heart Circ Physiol
290, H55-H63
|Abstract »|Full Text »|PDF »
Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-{alpha}.
T. C. Martinsen, I. Bakke, D. Chen, A. K. Sandvik, K. Zahlsen, T. Aamo, and H. L. Waldum (2005)
Am J Physiol Gastrointest Liver Physiol
289, G1052-G1060
|Abstract »|Full Text »|PDF »
Activation of Peroxisome Proliferator-Activated Receptor {alpha} by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors.
X. Fang, S. Hu, T. Watanabe, N. L. Weintraub, G. D. Snyder, J. Yao, Y. Liu, J. Y.-J. Shyy, B. D. Hammock, and A. A. Spector (2005)
J. Pharmacol. Exp. Ther.
314, 260-270
|Abstract »|Full Text »|PDF »
Oxidative Stress and Peroxisome Proliferator-Activated Receptors: Reversing the Curse?.
P. R. Devchand, O. Ziouzenkova, and J. Plutzky (2004)
Circ. Res.
95, 1137-1139
|Full Text »|PDF »
(
